S12 Ep30: Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD
In today’s episode, OncLive teamed up with CURE to present a discussion with David A. Braun, MD, PhD, about his research on determinants of response to immune checkpoint inhibition (ICI) in patients with renal cell carcinoma (RCC). Dr Braun is an assistant professor of medicine (medical oncology), the Louis Goodman and Alfred Gilman Yale Scholar, and a member of the Center of Molecular and Cellular Oncology at Yale Cancer Center in New Haven, Connecticut.
In this exclusive interview, Dr Braun discussed the rationale for investigating molecular factors that contribute to exceptional ICI…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.